Mid-term Results Demonstrate Salvage High-Intensity Focused Ultrasound (HIFU) as an Effective and Acceptably Morbid Salvage Treatment Option for Locally Radiorecurrent Prostate Cancer

European Urology

Volumn 55, Issue 3, 2009, Pages 640-649

  Murat, Francois Joseph ^a,b   Poissonnier, Laura ^b   Rabilloud, Muriel ^c   Belot, Aurélien ^c,d   Bouvier, Raymonde ^b   Rouviere, Olivier ^a   Chapelon, Jean Yves ^e   Gelet, Albert ^b  

^a Clinique du Val d'Ouest   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^e INSERM   (France)

Author keywords

HIFU; Prostate cancer; PSA; Radiation failure; Salvage; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; THERAPY EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION;

HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; ULTRASONIC THERAPY;

EID: 58849107672     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.04.091     Document Type: Article

References (30)

1. Kuban D.A., Thames H.D., Levy L.B., et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57 (2003) 915-928
2. Crook J., Malone S., Perry G., Bahadur Y., Roberston S., and Abdolell M. Post radiotherapy prostate biopsies: what do they really mean? Results in 498 patients. Int J Radiation Oncol Biol Phys 48 (2000) 355-367
3. Pollack A., Zagars G.K., Antolak J.A., Kuban D.A., and Rosen I.I. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 54 (2002) 677-685
4. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 66 (2001) 876-881
5. Zagars G.K., Pollack A., and Von Eschenbach A.C. Prostate cancer and radiotherapy-the message conveyed by serum prostate specific antigen. Int J Radiat Oncol Biol Phys 33 (1995) 23-35
6. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with the three-dimensional conformal radiotherapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
7. Hanks G.E., Martz K.L., Krall J.M., and Diamond J.J. Analysis of independent variables affecting survival after radiorecurrence of prostate cancer. Int J Radiat Oncol Bio Phys 16 (1989) 1431-1435
8. Lee W.R., Hanks G.E., and Hanlon A. Increasing prostate specific antigen profile following definitive radiotherapy for localized prostate cancer: clinical observations. J Clin Oncol 15 (1997) 220-238
9. Coen J.J., Zietman A.L., Thakral H., and Shipley W. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 20 (2002) 3199-3204
10. Ward J.F., Sebo T.J., Blute M.L., and Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 173 (2005) 1156-1160
11. Bianco F.J., Scardino P.T., Stephenson A.J., Di Blasio C.J., Fearn P.A., and Eastham J.A. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 448-453
12. Sanderson K.M., Penson D.F., Cai J., et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol 176 (2006) 2025-2031
13. Bahn D.K., Lee F., Silverman P., et al. Salvage cryosurgery for recurrent prostate cancer after radiotherapy: a seven-year follow-up. Clin Prostate Cancer 2 (2003) 111-114
14. Katz A.E., and Ghafar M.A. Selection of salvage cryotherapy patients. Rev Urol 2 (2002) 18-23
15. Donnelly B.J., and Saliken J.C. Salvage cryosurgery-how I do it?. Rev Urol 4 (2002) 24-29
16. Ng C.K., Moussa M., Downey D.B., and Chin J.L. Salvage cryoablation of the prostate: follow-up and analysis of predictive factors for outcome. J Urol 178 (2007) 1253-1257
17. Losa A., Nava L.D., Di Muzio N., et al. Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy. Urology 62 (2003) 1068-1072
18. Gelet A., Chapelon J.Y., Poissonnier L., et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63 (2004) 625-629
19. Rukstalis D.B. Treatment options after failure of radiation therapy-a review. Rev Urol 4 (2002) 12-17
20. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int Radiation Oncology Biol Phys 65 (2006) 965-974
21. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
22. Crook J.M., Perry G.A., Robertson S., et al. Routine prostate biopsies following radiotherapy for prostatic cancer: results for 226 patients. Urology 45 (1995) 624-631
23. Rosser C.J., Kuban D.A., Levy L.B., et al. Prostate-specific antigen bounce phenomenon after external beam radiation for localized prostate cancer. J Urol 168 (2002) 2001-2005
24. Jana S., and Blaufox M.D. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 36 (2006) 73-92
25. Heinisch M., Dirisamer A., Loidl W., et al. Positron emission tomography/computed tomography with F-18-Fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5ng/ml?. Mol Imaging Biol 8 (2006) 43-48
26. Ghanem N., Uhl M., Brink I., et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT, and PET/CT or the detection of metastases of bone. Eur J Radiol 55 (2005) 41-55
27. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499
28. Grado G.L., Collins J.M., Kriegshauser J.S., et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53 (1999) 2-10
29. Ward J.F., Blute M.L., Slezak J., Bergstralh E.J., and Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170 (2003) 1872-1876
30. Ward J.F., Zincke H., Bergstralh E.J., Slezak J.M., and Blute M.L. Prostate-specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172 (2004) 2244-2248